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Conclusions: RT±CT achieve good LC rates in anal canal cancer 
patients. In our experience, local response and LC statistically 
influenced the Cancer Specific Survival and the risk of systemic 
relapse. High acute skin toxicity rates probably impose to tailor 
volumes and techniques of irradiation following the patient and tumor 
characteristics (more tailored indications for inguinal RT?). 
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Purpose/Objective: Chemoradiation is worldwide considered the 
standard treatment of anal cancer, with a high rate of sphincter 
preservation, local control and survival. However, this strategy often 
leads to significant acute morbidity, playing a negative impact on 
clinical outcome. New technological advances could improve dose 
delivery and therapeutic index ratio. As IMRT allows simultaneous 
integrated boost (SIB) of higher RT doses to the gross tumor volume 
and lower doses to normal tissue, our purpose is to evaluate if this 
recently introduced technique can result in a better outcome in terms 
of tolerance and clinical results for patients affected by anal 
carcinoma. 
Materials and Methods: Between February 2009 and October 2012, 31 
patients, median age 62 years, with stage I (6 pts), II (6 pts), IIIA (8 
pts), IIIB (11 pts) were treated with RT±CT. 19 patients underwent 2 
courses of MMC and 5 FU (during the first and last week of RT); 3 pts 
received Capecitabine concurrent with RT; 3 pts received 
Capecitabine and MMC. IMRT with SIB was delivered by Helical 
Tomotherapy (HT) in 24 patients and by a Linac-based step & shoot 
technique in 7. The prescribed doses were 50.6-55 Gy to CTV1 
(primary tumor, involved nodes and high risk area) and 41.4-45 Gy to 
CTV2 (low risk subclinical disease), in 23-25 daily fractions. 
Megavoltage CT scans were obtained for patient alignment before 
each treatment in the group treated with HT while weekly portal 
images were performed in the other group. The clinical status during 
RT was analyzed through the evaluation of supportive care type 
defined by analgesic need. 
Results: All patients received the prescribed dose and none had 
treatment breaks due to acute toxicity, except for one, who refused 
to conclude treatment, receiving 50.6 Gy on CTV1 in 23 fractions. For 
all patients, dose volumes results for CTVs are reported in the table. 
Mean doses to bladder and bowel were respectively 28.5 and 16.4 Gy. 
The median follow-up is 12 months (range 1-36). The most significant 
severe genitourinary acute toxicities reported at treatment end were 
grade 3 vaginal bleeding (3%) and grade 2 vaginal burn (6%). 
Cutaneous grade 3 erythema was recorded in 20% of patients and 
grade 2 gastrointestinal toxicities in 16%. Generally, skin toxicity 
appeared in the last week of RT and recovered in 2 weeks. 16 (53%) 
patients needed analgesic support (tramadol, codeine or major 
opioids). At a minimum FU of 4 months, 22 patients are evaluable for 
clinical response: 19 (86%) patients achieved complete response (CR), 
2 patients underwent local progression after initial partial response 
(PR) and one patient had progressive disease (PD). One patient died 
for PD. 
 
 
 
 
 
 
 
 
 
 
Conclusions: IMRT with SIB achieves great homogeneity in the dose 
distribution and a significantly good sparing of the organs at risk, also 
shortening total treatment time. The combined chemo-radiotherapy 
also shows excellent results in terms of toxicity and local control.  
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Purpose/Objective: Stereotactic Body Radiation Therapy (SBRT) take 
advantage of the prostate low a/b ratio to deliver a large radiation 
dose in few fractions. Recent technological developments, combined 
with modern understanding on prostate radiobiology have generated 
enthusiasm for hypofractionated regimens. We report our preliminary 
results with Cyberknife stereotactic radiosurgery in patients with 
clinically localized prostate cancer. 
 Materials and Methods: From July 2007 to October 2011, 107 
patients with a median age of 75 (range 60– 86) years, a T1c –T2 b 
prostate cancer were treated with Cyberknife stereotactic 
radiosurgery at our institution. The majority of patients 59 (55%) were 
low risk , 28 pts (26%) were intermediate risk and 19 pts (19%) were 
high risk patients using the NCCN criteria . Pre-treatment PSAs ranged 
from 1.75 to 23.88 ng.ml (median 7.4 ng.ml). Among the entire study 
cohort 7 of 19 high risks patients received androgen deprivation 
therapy (ADT), ADT was not administered to any low – intermediate 
risk patients A prescribed dose of 38 Gy in four fractions was delivered 
to the PTV, which was defined as the prostate (plus seminal vesicles 
in High risk patients) expanded 3 mm posteriorly and 5 mm elsewhere. 
Real-time intrafractional motion tracking was used. Biochemical 
control was assessed using the nadir+2 (Phoenix) definition.  
Results: All patients were placed on A-blockade medication at the 
beginning of Cyberknife radiosurgery treatment. Acute side effects 
were generally mild and resolved shortly after treatment. No rtog 
grade 4 acute or late ractal/urinary complications was observed. 3 
patients developed Grade 3 late urinary toxicity following repeated 
urological instrumentation, including cistoscopy and urethral 
dilatation. Four patients, one with prior Turp, experienced 
incontinence, one 9 months after treatment, two 12 months after 
treatment, one 27 months later. One patient experienced rectal 
incontinence 12 months after treatment. The actuarial median follow 
up is 30 months (range 12 – 60 months). The four years actuarial psa 
relapse free survival rate is 93.9% (CI: 88.0%-99..8%). To date 5 
patients failed biochemically. One low risk patient revealed local 
relapse 30 months after Cyberknife treatment. One high risk patient 
developed bone metastases, in 2 intermediate and in 1 high risk 
patient we observed nodal metastases. All patients are alive except 
four died of unrelated causes. 
Conclusions: Cyberknife SBRT produces excellent biochemical control 
rates at up to 4 years with mild toxicity and minimal impact on quality 
of life. Median PSA levels compare favourably with other radiation 
Volume/Gy Prescription 
Dose (Gy) 
Mean 
Dose 
Max 
Dose 
Min 
Dose 
CTV55 55 54.9 56.8 51.4 
CTV50.6 50.6 51 52.9 47.7 
CTV45 45 47 55.9 38.4 
CTV41.4 41.4 42.5 52 39.3 
